Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE3UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 1996

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Detox-B adjuvant

BIOLOGICAL

recombinant interferon alfa

Trial Locations (27)

14623

Interlakes Oncology/Hematology PC, Rochester

27710

Duke Comprehensive Cancer Center, Durham

30322

Emory University School of Medicine, Atlanta

32803

Adventist Health System/Sunbelt, Inc., Orlando

33136

Sylvester Cancer Center, University of Miami, Miami

35294

University of Alabama Comprehensive Cancer Center, Birmingham

40202

University of Louisville Hospital, Louisville

43206

CCOP - Columbus, Columbus

43235

Hematology Oncology Consultants Inc, Columbus

45219

Barrett Cancer Center, The University Hospital, Cincinnati

Christ Hospital, Cincinnati

60068

Lutheran General Cancer Care Center, Park Ridge

78705

Southwest Regional Cancer Center, Austin

87131

University of New Mexico Cancer Research & Treatment Center, Albuquerque

91010

Beckman Research Institute, City of Hope, Duarte

94115

Kaiser Permanente Medical Group - San Francisco, San Francisco

94589

Kaiser Permanente Medical Center - Vallejo, Vallejo

94611

Kaiser Permanente Medical Center - Oakland, Oakland

95825

Kaiser Permanente Medical Center-Sacramento, Sacramento

92093-0686

University of California San Diego Cancer Center - La Jolla, La Jolla

94115-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

95051-5386

Kaiser Permanente Medical Center - Santa Clara, Santa Clara

06360-7106

University of Connecticut Health Center, Farmington

06520-8028

Yale Comprehensive Cancer Center, New Haven

68131-2197

Creighton University Cancer Center, Omaha

03756

Norris Cotton Cancer Center, Lebanon

97201-3098

Oregon Cancer Center at Oregon Health Sciences University, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY